Boai NKY Pharmaceuticals Ltd - Asset Resilience Ratio
Boai NKY Pharmaceuticals Ltd (300109) has an Asset Resilience Ratio of 0.51% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Boai NKY Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Boai NKY Pharmaceuticals Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Boai NKY Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Boai NKY Pharmaceuticals Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥22.21 Million | 0.51% |
| Total Liquid Assets | CN¥22.21 Million | 0.51% |
Asset Resilience Insights
- Limited Liquidity: Boai NKY Pharmaceuticals Ltd maintains only 0.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Boai NKY Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Boai NKY Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cngr Advanced Material Co Ltd
SHE:300919 |
Specialty Chemicals | 0.52% |
|
Luxi Chemical Group Co Ltd
SHE:000830 |
Specialty Chemicals | 0.43% |
|
Guangdong HongDa Blasting Co Ltd
SHE:002683 |
Specialty Chemicals | 1.05% |
|
Lily Group Co Ltd
SHG:603823 |
Specialty Chemicals | 0.37% |
|
Lianhe Chemical Technology Co Ltd
SHE:002250 |
Specialty Chemicals | 0.44% |
|
Shandong Link Science and Technology Co Ltd
SHE:001207 |
Specialty Chemicals | 18.99% |
|
Shenzhen WOTE Advanced Materials Co Ltd
SHE:002886 |
Specialty Chemicals | 3.77% |
|
New East New Materials Co Ltd
SHG:603110 |
Specialty Chemicals | 6.08% |
Annual Asset Resilience Ratio for Boai NKY Pharmaceuticals Ltd (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Boai NKY Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.54% | CN¥23.79 Million ≈ $3.48 Million |
CN¥4.37 Billion ≈ $639.22 Million |
-0.16pp |
| 2024-12-31 | 0.71% | CN¥30.98 Million ≈ $4.53 Million |
CN¥4.37 Billion ≈ $639.77 Million |
-0.14pp |
| 2023-12-31 | 0.85% | CN¥34.20 Million ≈ $5.00 Million |
CN¥4.02 Billion ≈ $588.21 Million |
-0.01pp |
| 2022-12-31 | 0.86% | CN¥31.99 Million ≈ $4.68 Million |
CN¥3.71 Billion ≈ $543.41 Million |
-4.19pp |
| 2021-12-31 | 5.06% | CN¥201.71 Million ≈ $29.52 Million |
CN¥3.99 Billion ≈ $583.85 Million |
+3.97pp |
| 2020-12-31 | 1.09% | CN¥45.03 Million ≈ $6.59 Million |
CN¥4.15 Billion ≈ $606.61 Million |
+2.72pp |
| 2019-12-31 | -1.63% | CN¥-68.37 Million ≈ $-10.00 Million |
CN¥4.20 Billion ≈ $614.11 Million |
-1.22pp |
| 2018-12-31 | -0.41% | CN¥-9.48 Million ≈ $-1.39 Million |
CN¥2.30 Billion ≈ $337.02 Million |
-0.32pp |
| 2017-12-31 | -0.09% | CN¥-1.83 Million ≈ $-268.20K |
CN¥1.96 Billion ≈ $286.61 Million |
-3.22pp |
| 2016-12-31 | 3.13% | CN¥41.00 Million ≈ $6.00 Million |
CN¥1.31 Billion ≈ $191.68 Million |
+3.19pp |
| 2015-12-31 | -0.06% | CN¥-725.33K ≈ $-106.14K |
CN¥1.24 Billion ≈ $180.86 Million |
-- |
| 2010-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥357.81 Million ≈ $52.36 Million |
-- |
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, or… Read more